title: Ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2).
abstract: We investigated ectopic bone formation by biphasic calcium phosphate (BCP) combined with recombinant human bone morphogenetic protein-2 (rhBMP-2) in the rat dorsum. Under reduced pressure, rhBMP-2 was adsorbed onto BCP, which consisted of 80% beta-tricalcium phosphate and 20% hydroxyapatite uniformly distributed in granules. Twenty Wistar rats were separated into 4 groups consisting of 5 animals each dosed with 2, 10, and 50 micrograms/700 microliters of rhBMP-2 and a control group (BCP only). Pieces of the BCP-BMP complex or only BCP were implanted under the dorsal skin of the rats. Histological sections were examined three weeks later. New bone was formed in all rats given 50 micrograms doses, but not in the 2 micrograms and control groups. These results indicated that BCP combined with rhBMP-2 induced ectopic bone formation without additional carriers. Therefore, BCP granules alone can function as carriers for rhBMP-2 to induce bone formation.
authors.affiliation: Department of Periodontology, Faculty of Dentistry, Tokyo Medical and Dental University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Oda
authors.forename: A
authors.initials: A
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Higuchi
authors.forename: T
authors.initials: T
authors.lastname: Shizuya
authors.forename: I
authors.initials: I
authors.lastname: Ishikawa
mesh_terms: D000327:Adsorption; D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000502:physiology; D001842:Bone and Bones / Q000473:pathology; D002130:Calcium Phosphates / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D062109:Dermatologic Surgical Procedures; D004337:Drug Carriers; D004338:Drug Combinations; D015726:Giant Cells / Q000473:pathology; D006801:Humans; D006882:Hydroxyapatites / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D008297:Male; D009999:Ossification, Heterotopic / Q000473:pathology / Q000503:physiopathology*; D010006:Osteoblasts / Q000473:pathology; D010012:Osteogenesis / Q000502:physiology; D010316:Particle Size; D011312:Pressure; D019736:Prostheses and Implants; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D013499:Surface Properties; D016212:Transforming Growth Factor beta
chemical_list: C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D002130:Calcium Phosphates; D004337:Drug Carriers; D004338:Drug Combinations; D006882:Hydroxyapatites; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C485828:alpha-tricalcium phosphate; C074950:hydroxyapatite-beta tricalcium phosphate; C499469:recombinant human bone morphogenetic protein-2; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous